La vendita allo scoperto per Veradigm dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Veradigm. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Veradigm (OTC:MDRX) Azioni, Report sulle vendite allo scoperto

Veradigm

Veradigm Inc is a healthcare technology company that drives value through its various combinations of platforms, data, expertise, connectivity, and scale. The company delivers a combination of point-of-care clinical and financial solutions. The Veradigm Network features a dynamic community of solutions and partners providing insights, technology, and data-driven solutions for the healthcare provider, payer, and Life Science markets.

Allscripts Healthcare

Veradigm Inc

Stephens &amp; Co. analyst Jeff Garro maintains Veradigm (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#OTC">MDRX</a>) with a Equal-Weight and raises the price target from $7 to $13.

News

Price Target

Analyst Ratings

MDRX

Stephens & Co. Maintains Equal-Weight on Veradigm, Raises Price Target to $13

<a href="https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts" title="https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts">https://www.axios.com/pro/health-tech-deals/2024/11/10/mckesson-oracle-veradigm-bidders-allscripts</a>

ORCL

Reported November 10, 2024 'McKesson And Oracle Are Among The Final Bidders Vying To Acquire EMR Data Company Veradigm' - Axios

TD Cowen analyst Charles Rhyee maintains Veradigm (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#OTC">MDRX</a>) with a Buy and lowers the price target from $26 to $15.

TD Cowen Maintains Buy on Veradigm, Lowers Price Target to $15

Deutsche Bank analyst George Hill downgrades Veradigm (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#OTC">MDRX</a>) from Buy to Hold and lowers the price target from $15 to $10.

Downgrades

Deutsche Bank Downgrades Veradigm to Hold, Lowers Price Target to $10

Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&amp;P SmallCap 600.&nbsp;

Sprinklr To Replace Veradigm In S&P SmallCap 600 Effective Prior To Opening Of Trading On March 4, 2024

Investors with a lot of money to spend have taken a bullish stance on Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MDRX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Veradigm.
This isn't normal.
The overall sentiment of these big-money traders is split between 64% bullish and 35%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $513,405, and 5 are calls, for a total amount of $213,692.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $7.5 for Veradigm, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Veradigm's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Veradigm's substantial trades, within a strike price spectrum from $5.0 to $7.5 over the preceding 30 days.
<h3>Veradigm Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709139665_0_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$5.00</td>
<td>$100.0K</td>
<td>7.7K</td>
<td>9.1K</td>
</tr>
<tr>
<td>MDRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$5.00</td>
<td>$100.0K</td>
<td>7.7K</td>
<td>6.1K</td>
</tr>
<tr>
<td>MDRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$5.00</td>
<td>$75.0K</td>
<td>7.2K</td>
<td>2.5K</td>
</tr>
<tr>
<td>MDRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$7.50</td>
<td>$66.1K</td>
<td>13.7K</td>
<td>999</td>
</tr>
<tr>
<td>MDRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/15/24</td>
<td>$7.50</td>
<td>$56.0K</td>
<td>8.3K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Veradigm</h3>
Veradigm Inc is a healthcare technology company that drives value through its various combination of platforms, data, expertise, connectivity, and scale. It delivers a combination of point-of-care clinical and financial solutions. The Veradigm Network features a dynamic community of solutions and partners providing insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.
Following our analysis of the options activities associated with Veradigm, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Veradigm</h3>
<ul>
<li>Trading volume stands at 14,018,267, with MDRX's price down by -8.68%, positioned at $6.94.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Veradigm options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Market Whales and Their Recent Bets on MDRX Options

WIIM

Veradigm shares are trading lower after the company announced it will acquire ScienceIO.

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million. </li>
<li>Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) shares moved upwards by 20.93% to $90.0. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares rose 19.5% to $12.25. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares decreased by 22.9% to $0.33 during Tuesday's pre-market session. The company's market cap stands at $28.0 million. </li>
<li>Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>) shares decreased by 22.03% to $6.48. The market value of their outstanding shares is at $708.0 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares decreased by 18.32% to $13.07. The market value of their outstanding shares is at $53.1 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares fell 14.79% to $1.21. The market value of their outstanding shares is at $31.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares fell 11.54% to $1.15. The company's market cap stands at $56.4 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock fell 10.23% to $0.43. The market value of their outstanding shares is at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BEAT

BSGM

CDXS

DTIL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JANX

LGND

MNOV

NRXP

TMDX

VKTX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

The transaction will be funded through cash on hand and is not subject to a financing condition. The purchase price to be paid for ScienceIO is&nbsp;$140 million&nbsp;in cash (subject to customary adjustments for cash, indebtedness, working capital and transaction expenses), an aggregate of approximately&nbsp;$44 million&nbsp;of which is deferred and substantially all of which is payable in installments on each of the first three anniversaries of the closing date.&nbsp;The Company has reaffirmed the estimated, unaudited ranges of financial information for fiscal 2023 that it provided on January 10, 2024

Veradigm Signs Definitive Agreement To Acquire ScienceIO For Purchase Price To Be Paid Of $140M Cash

The Company also announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan in anticipation of notification from Nasdaq that it will suspend trading in the stock.

Veradigm Expects Not To File Required Financial Statements By Nasdaq's February 27, 2024 Deadline; Says Working Diligently To File Required Financial Statements And Restore Listing

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDRX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/15/24</td>
<td>$7.50</td>
<td>$67.5K</td>
<td>17.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IBRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.00</td>
<td>$39.4K</td>
<td>113</td>
<td>759</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$110.00</td>
<td>$237.5K</td>
<td>1.0K</td>
<td>563</td>
</tr>
<tr>
<td>BCRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.00</td>
<td>$52.5K</td>
<td>1.1K</td>
<td>512</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$13.00</td>
<td>$25.2K</td>
<td>81.4K</td>
<td>454</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$500.00</td>
<td>$29.8K</td>
<td>285</td>
<td>333</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$36.0K</td>
<td>7.3K</td>
<td>244</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$310.00</td>
<td>$34.0K</td>
<td>300</td>
<td>167</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$130.00</td>
<td>$31.1K</td>
<td>8.4K</td>
<td>165</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$260.00</td>
<td>$52.0K</td>
<td>101</td>
<td>100</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding MDRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>), we observe a put option trade with bullish sentiment. It expires in 18 day(s) on March 15, 2024. Parties traded 900 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $67.5K, with a price of $75.0 per contract. There were 17810 open contracts at this strike prior to today, and today 2098 contract(s) were bought and sold. 
• Regarding IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we observe a call option trade with bearish sentiment. It expires in 690 day(s) on January 16, 2026. Parties traded 197 contract(s) at a $4.00 strike. The total cost received by the writing party (or parties) was $39.4K, with a price of $200.0 per contract. There were 113 open contracts at this strike prior to today, and today 759 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a put option trade with bearish sentiment. It expires in 326 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $237.5K, with a price of $475.0 per contract. There were 1063 open contracts at this strike prior to today, and today 563 contract(s) were bought and sold. 
• For BCRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>), we notice a call option trade that happens to be bullish, expiring in 326 day(s) on January 17, 2025. This event was a transfer of 500 contract(s) at a $8.00 strike. The total cost received by the writing party (or parties) was $52.5K, with a price of $105.0 per contract. There were 1186 open contracts at this strike prior to today, and today 512 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 116 day(s) on June 21, 2024. This event was a transfer of 200 contract(s) at a $13.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.2K, with a price of $126.0 per contract. There were 81418 open contracts at this strike prior to today, and today 454 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option sweep that happens to be bearish, expiring in 53 day(s) on April 19, 2024. This event was a transfer of 122 contract(s) at a $500.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.8K, with a price of $240.0 per contract. There were 285 open contracts at this strike prior to today, and today 333 contract(s) were bought and sold. 
• Regarding TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we observe a call option trade with bullish sentiment. It expires in 326 day(s) on January 17, 2025. Parties traded 40 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $902.0 per contract. There were 7323 open contracts at this strike prior to today, and today 244 contract(s) were bought and sold. 
• Regarding CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we observe a put option trade with bullish sentiment. It expires in 81 day(s) on May 17, 2024. Parties traded 81 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $420.0 per contract. There were 300 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bearish, expiring in 81 day(s) on May 17, 2024. This event was a transfer of 76 contract(s) at a $130.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.1K, with a price of $410.0 per contract. There were 8454 open contracts at this strike prior to today, and today 165 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option trade with bullish sentiment. It expires in 480 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $52.0K, with a price of $1040.0 per contract. There were 101 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

IBRX

TEVA

TGTX

10 Health Care Stocks With Whale Alerts In Today's Session

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fveradigm.com%2F&amp;esheet=53895514&amp;newsitemid=20240213633285&amp;lan=en-US&amp;anchor=Veradigm+Inc.&amp;index=1&amp;md5=282aa5a4459984b3e7a405da5df96e4a">Veradigm Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education.
Influenza vaccination is associated with a lower risk for adverse cardiovascular events, with an overall 34% lower risk of major adverse cardiovascular events and a 45% lower risk among individuals with recent acute coronary syndrome (ACS).1 As part of this quality improvement initiative, Veradigm is delivering ACC-sponsored vaccination education messaging to a subset of cardiology practices using the Practice Fusion EHR (a Veradigm Network solution). The messages appear as banner advertisements in an in-frame window adjacent to the EHR workflow that is separate and distinguishable from the clinical and practice management workflow within the EHR.
"Veradigm is proud to be working with the ACC to apply our real-world data in combination with our messaging capabilities to improve rates of recommended vaccinations for adults with cardiovascular disease," said Stuart Green, Senior Vice President and General Manager at Veradigm.
"Routine influenza vaccination is an important component of the evidence-based practice in patients with cardiovascular disease, but like many other cardiovascular treatments, deep implementation gaps exist," said Ankeet S. Bhatt, MD, MBA, ScM, chair of the TRANSFORM VAX project steering committee. "Together with Veradigm, the ACC is studying how to reach clinicians in innovative ways to provide timely, actionable information to close implementation gaps in influenza vaccination for at-risk cardiovascular patients."
Powered by Veradigm de-identified real-world data, TRANSFORM VAX will deliver educational messaging to healthcare providers whose patient cohorts meet ACC-determined criteria for inclusion. It will then compare results against a control group of physicians not receiving TRANSFORM VAX messaging, enabling the ACC to establish benchmarks from which to measure future quality improvement success.
"People with heart disease have a much higher risk of serious complications from the flu, including heart attack, stroke and heart failure," said Ami Bhatt, MD, ACC Chief Innovation Officer. "The ACC is committed to delivering innovative solutions to transform cardiovascular care and improve heart health by raising clinician awareness of the benefits of flu vaccination for the most at-risk patients."
Veradigm Inc.'s participation in TRANSFORM VAX is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsecure-web.cisco.com%2F1FE9ZZkIGcStC_KQsc8BSWm52ABivDTLMmrYefqtDyTVZr5ROF1za_wRdRb8zYScTsGbfbb4q9kfN7PljzkpdMdNpHm2xauOG8ngcavmLRaePqXx9vcG8GoJtRafwU3lxGyuXzJbgifcYdPGpkK8yUfueRBDPjWjfKWEGW965ivyBKbmMIQ5-z7LKqqVUjKS2QyDLuXetbdEFf5rmHufsY2xFHX7-RyDJ41La-FEmoU3-vXBc7XZHatsNMs5WH3aHKrXgan7qIgtzYPDLhi9-f-wzUn8v4cLfoMseJ5ToGWKe16H1dHnO5DwjmCJkKWVYK_9x_KrJRS9c0vrp89OcjPT5SAC6WU_8KL9j_MUPyFLYAHYuLOzQ4uVetTrbZSVtR17JeWTcOyCZjJzWeJ1JkwyWdycLuG_sp-BM77xyQkU%2Fhttps%253A%252F%252Fcmss-ssaai.org%252F&amp;esheet=53895514&amp;newsitemid=20240213633285&amp;lan=en-US&amp;anchor=financial+assistance+award+to+the+Council+of+Medical+Specialty+Societies+%28CMSS%29&amp;index=2&amp;md5=06c0c9d7c280a73e650b928c0befdb76">financial assistance award to the Council of Medical Specialty Societies (CMSS)</a>, with 100 percent funded by CDC/HHS. The contents are those of the authors and do not necessarily represent the official views of nor endorsement, by CDC/HHS or the U.S. Government.

Biotech

General

Veradigm And American College Of Cardiology Launch Influenza Vaccination Education Initiative To Improve Cardiovascular Health

RBC Capital analyst Sean Dodge maintains Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>) with a Outperform and lowers the price target from $22 to $11.

RBC Capital Maintains Outperform on Veradigm, Lowers Price Target to $11

Shares of WD-40 Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wdfc#NASDAQ">WDFC</a>) rose sharply during Wednesday&rsquo;s session after the company reported better-than-expected first-quarter results.
WD-40 reported quarterly earnings of $1.28 per share which exceeded the analyst consensus estimate of $1.05 per share. The company reported quarterly sales of $140.42 million, clocking in above the Street&#39;s estimate of $134.37 million.
WD-40 shares jumped 17.3% to $277.56 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Nauticus Robotics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kitt#NASDAQ">KITT</a>) climbed 87.8% to $0.5501. Nauticus Robotics secured additional funding and appointed John W. Gibson, Jr as interim CEO.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) shares jumped 47.7% to $3.0570. Clearmind Medicine completed a Type A Meeting with the FDA for clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of alcohol use disorder.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) gained 46.8% to $7.57. Sana Biotechnology recently announced FDA clearance of investigational new drug application for SC262.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) jumped 37.8% to $4.98.</li>
<li>Vicarious Surgical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NASDAQ">RBOT</a>) rose 37% to $0.6851.</li>
<li>Nvni Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvni#NASDAQ">NVNI</a>) climbed 35.2% to $2.6091.</li>
<li>EchoStar Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sats#NASDAQ">SATS</a>) gained 31% to $16.50. EchoStar completed merger with DISH Network Corporation.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) climbed 28.8% to $1.25 after the company reported strong preliminary FY23 total revenues.</li>
<li>Exicure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xcur#NASDAQ">XCUR</a>) shares rose 17% to $0.5501. Exicure was granted broad U.S. patent #11866700 for &quot;Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin 17 Mrna (For Inflammation From Cancer, Obesity, Diabetes, Alzheimer&#39;s).&quot;</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) gained 16.2% to $13.72.</li>
<li>Exscientia plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exai#NASDAQ">EXAI</a>) rose 14% to $7.07. B of A Securities recently downgraded the stock from Buy to Neutral and lowered its price target from $11 to $9.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nams#NASDAQ">NAMS</a>) rose 13.6% to $14.00.</li>
<li>SMART Global Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgh#NASDAQ">SGH</a>) gained 13.4% to $20.97 after the companyy posted better-than-expected earnings for its first quarter and announced approval of $75 million share repurchase authorization.</li>
<li>Xeris Biopharma Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xers#NASDAQ">XERS</a>) jumped 12.4% to $2.7100. Xeris Biopharma entered into an exclusive worldwide license agreement with Amgen for Xeriject formulation of teprotumumab for thyroid eye disease.</li>
<li>GoodRx Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdrx#NASDAQ">GDRX</a>) jumped 11.6% to $6.38. GoodRx sees preliminary FY23 adjusted revenue of $759 million to $761 million.</li>
<li>E2open Parent Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/etwo#NYSE">ETWO</a>) surged 11.2% to $4.27 following strong quarterly sales.</li>
<li>PriceSmart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psmt#NASDAQ">PSMT</a>) rose 10% to $80.25 as the company reported better-than-expected earnings for its first quarter on Tuesday.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares rose 9.3% to $1.4203. iCoreConnect announced strategic acquisition of Verifi Dental.</li>
<li>AZZ Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/azz#NYSE">AZZ</a>) jumped 9.1% to $62.24 following upbeat quarterly results.</li>
<li>Intuitive Surgical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) gained 6.1% to $350.63. Intuitive Surgical said it sees preliminary revenue of $1.93 billion for the fourth quarter, versus market estimates of $1.87 billion.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>DocGo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcgo#NASDAQ">DCGO</a>) shares fell 32.9% to $3.2150. Fuzzy Panda Research issued a report and disclosed a short position in the stock.</li>
<li>HWH International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwh#NASDAQ">HWH</a>) shares fell 25.3% to $2.10 after dipping 26% on Tuesday.</li>
<li>Aclaris Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrs#NASDAQ">ACRS</a>) fell 25% to $0.9601 after the company&#39;s Phase 2B study of ATI-1777 2% QD was not statistically superior on the primary efficacy endpoint.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) fell 19.5% to $0.3127.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) shares fell 18.8% to $2.3557 after dipping over 27% on Tuesday. Roma Green Finance announced pricing of $12.3 million public offering of 2,449,943 of shares at price of $4.00 per share.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) fell 16.8% to $14.11. Sidus Space regained compliance with Nasdaq minimum bid requirements.</li>
<li>Wearable Devices Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlds#NASDAQ">WLDS</a>) fell 15.7% to $0.3797.</li>
<li>Aehr Test Systems (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aehr#NASDAQ">AEHR</a>) shares fell 15.1% to $18.97 after the company lowered its full-year revenue guidance.</li>
<li>Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) fell 14.9% to $2.22.</li>
<li>GrafTech International Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eaf#NYSE">EAF</a>) fell 14.4% to $1.61.</li>
<li>Alaunos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrt#NASDAQ">TCRT</a>) declined 12.9% to $0.1335.</li>
<li>TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) fell 12.4% to $18.38 after the company reported preliminary BRIUMVI US net product sales for Q4 and FY23.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) fell 12% to $4.2350.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) fell 11.9% to $0.2621 after gaining 22% on Tuesday.</li>
<li>Veradigm Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdrx#NASDAQ">MDRX</a>) fell 11.1% to $9.56. Veradigm said it sees FY23 revenue of $608 million to $622 million.</li>
<li>Galera Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grtx#NASDAQ">GRTX</a>) shares fell 9.1% to $0.1919 after jumping 41% on Tuesday.</li>
<li>Saratoga Investment Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sar#NYSE">SAR</a>) fell 9.1% to $23.55 following downbeat quarterly earnings.</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) declined 8.8% to $13.43.</li>
<li>Sasol Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ssl#NYSE">SSL</a>) shares fell 6.8% to $9.08.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36571171/how-to-earn-500-a-month-from-jpmorgan-stock-ahead-of-q4-earnings-report"> How To Earn $500 A Month From JPMorgan Stock Ahead Of Q4 Earnings Report</a>

Penny Stocks

Small Cap

Intraday Update

Trading Ideas

ACRS

AEHR

AIMD

AMRN

CMND

DCGO

ETWO

EXAI

GDRX

GRTX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ICCT

ISRG

KITT

NAMS

NEXI

NVCR

NVNI

PRST

PSMT

RBOT

ROMA

SANA

SATS

SIDU

TCRT

WDFC

WLDS

XCUR

XERS

Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Veradigm Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdrx#NASDAQ">MDRX</a>) shares are trading lower after it provided&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/24/01/b36574570/new-veradigm-leadership-provides-outlook-on-business-and-strategy-and-refreshed-financial-estimate" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">below-consensus FY23 guidance</a>.
For FY23, the company expects revenue (on a GAAP basis) of $608 million-$622 million (vs. $637.67 million estimate), including a favorable customer litigation settlement, contributing approximately $16 million on a GAAP basis that reflects services provided over prior years.
MDRX sees adjusted EBITDA of $122 million-$135 million for FY23, excluding around $16 million favorable customer litigation settlement and certain other legal settlements.
For FY23, the analyst projects adjusted EPS of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/calendars/guidance" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">$0.79-$0.88 vs. consensus of $0.89</a>.
As of December 31, 2023, net cash is estimated to be over $232 million, comprising cash and cash equivalents to exceed $440 million and debt of $208 million.
Lee Westerfield, Interim Chief Financial Officer said, &quot;The state of Veradigm is fundamentally healthy. Its financials rest on a solid foundation that is evident in its net cash position and its high-quality mix of recurring subscription revenue. We believe our fiscal health enables us to invest in strategic opportunities for growth, product initiatives for margin expansion, and share repurchases for returns to shareholders &ndash; all in all, fulfilling our mission to address unmet client needs for healthtech and to elevate ROI and shareholder value.&quot;&nbsp;
Last month, MDRX announced leadership changes amid an investigation into financial reporting. Greg Garrison is now Executive Chairman, Shih-Yin Ho is interim CEO and Lee Westerfield is interim CFO. Former CEO Richard J. Poulton and&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/news/23/12/36155581/why-veradigm-shares-are-trading-lower" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">CFO Leah S. Jones resigned</a>.
Price Action: MDRX shares are down 9.95% at $9.69 on the last check Wednesday.&nbsp;

Equities

Mid Cap

Guidance

Why Healthcare Data & Technology Solutions Provider Veradigm Shares Are Trading Lower Today

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday.
Shares of Veradigm Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdrx#NASDAQ">MDRX</a>) shares fell sharply during Wednesday&rsquo;s session.
Veradigm said it sees FY23 revenue of $608 million to $622 million. The company also sees FY23 Non-GAAP EPS of 79 cents to 88 cents.
Veradigm shares tumbled 11.1% to $9.56 on Wednesday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>DocGo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcgo#NASDAQ">DCGO</a>) shares dipped 32.9% to $3.2150. Fuzzy Panda Research issued a report and disclosed a short position in the stock.</li>
<li>Aehr Test Systems (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aehr#NASDAQ">AEHR</a>) shares declined 15.1% to $18.97 after the company lowered its full-year revenue guidance.</li>
<li>GrafTech International Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eaf#NYSE">EAF</a>) shares tumbled 14.4% to $1.61.</li>
<li>TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) declined 12.4% to $18.38 after the company reported preliminary BRIUMVI US net product sales for Q4 and FY23.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) declined 12% to $4.2350.</li>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) fell 10.2% to $6.92.</li>
<li>Saratoga Investment Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sar#NYSE">SAR</a>) declined 9.1% to $23.55 following downbeat quarterly earnings.</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) dipped 8.8% to $13.43.</li>
<li>Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) fell 8.3% to $2.73. Coherus Biosciences announced the termination of its tigit program collaboration with Shanghai Junshi Biosciences, with plans to wind down their work in the coming months.</li>
<li>Tilray Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) fell 8.1% to $1.94. Tilray filed prospectus supplement to register the resale of 12.4 million shares of common stock by selling stockholder.</li>
<li>Mirum Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mirm#NASDAQ">MIRM</a>) fell 7.7% to $25.75. Mirum Pharmaceuticals recently announced preliminary unaudited 2023 net revenue and issued corporate updates.</li>
<li>Sasol Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ssl#NYSE">SSL</a>) shares declined 6.8% to $9.08.</li>
<li>Wolfspeed, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wolf#NYSE">WOLF</a>) fell 6.7% to $37.35.</li>
<li>3D Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) fell 6.2% to $5.41.</li>
<li>iRobot Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irbt#NASDAQ">IRBT</a>) fell 6.1% to $34.81.</li>
<li>Arcadium Lithium plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/altm#NASDAQ">ALTM</a>) fell 6% to $6.11.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) shares declined 4.7% to $144.85 after the SEC&#39;s X account was compromised on Tuesday. The SEC said it has not approved the listing and trading of spot <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/">bitcoin</a> exchange-traded products.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36577360/dow-surges-100-points-pricesmart-earnings-top-views"> Dow Surges 100 Points; PriceSmart Earnings Top Views</a>

ALTM

CHRS

COIN

GLUE

IRBT

MIRM

TLRY

WOLF

Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday

Veradigm Sees FY23 Non-GAAP EPS $0.79-$0.88

Veradigm Sees FY23 Revenue $608M-$622M

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock increased by 29.8% to $0.8 during Wednesday's pre-market session. The company's market cap stands at $6.9 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 21.88% to $0.46. The market value of their outstanding shares is at $13.6 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares moved upwards by 21.33% to $110.0. The company's market cap stands at $852.5 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock increased by 15.78% to $1.1. The company's market cap stands at $38.7 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) shares increased by 15.35% to $1.12. The market value of their outstanding shares is at $457.2 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares increased by 12.99% to $0.6. The company's market cap stands at $7.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares fell 14.1% to $1.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $77.9 million. </li>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) stock decreased by 9.93% to $2.54. The market value of their outstanding shares is at $78.6 million. </li>
<li>Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>) stock decreased by 9.86% to $9.7. The market value of their outstanding shares is at $1.0 billion. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 8.87% to $0.85. The company's market cap stands at $2.5 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) stock decreased by 8.58% to $0.46. The market value of their outstanding shares is at $1.4 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares declined by 8.32% to $0.58. The company's market cap stands at $20.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

ESLA

FORA

TBIO

THMO

YCBD

ZJYL

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Providers using Veradigm EHRs to gain access to longitudinal patient records, improving interoperability and driving better treatment decisions
selected MedAllies as its Qualified Health Information Network (QHIN) partner.
&nbsp;
&nbsp;

Veradigm Partners With MedAllies

Press Releases

Veradigm Amends and Extends Stockholder Rights Plan

Veradigm Announces Board Expansion and Changes

Veradigm Becomes First EHR Media Platform to Achieve POCMA Certification

Over 3,500 Healthcare Practices Receive Gaps-in-Care Alerts at the Point-of-Care via Veradigm Payer Insights Solution

Veradigm to Release Financial Update March 18th and Host Investor Call March 19th

Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements

Veradigm Provides Updates on Fiscal 2023 and 2024 and an Outlook for Fiscal 2025

Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency

Black Book Ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solution Vendor in 2025

Comments

Veradigm

Vendite allo scoperto

Veradigm (OTC:MDRX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO